Dr. Jakob Dupont serves as the President and Chief Executive Officer of Affini-T Therapeutics, steering the precision cell therapy enterprise through its clinical development pipeline targeting oncogenic drivers. Bringing extensive clinical research and oncology leadership experience from prior executive roles at major biotechnology firms, he directs the company's innovative T-cell receptor therapy programs designed to address challenging solid tumors and transform cellular immunotherapy outcomes for cancer patients.